{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-002980","form_type":"8-K","ticker":null,"cik":"0001293971","company_name":"bluebird bio, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.260639+00:00","generated_at":"2026-06-20T18:38:31.194730+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"bluebird bio sells Rare Pediatric Disease PRV to Bristol-Myers Squibb for $95M cash","bullets":["Sold PRV awarded for ZYNTEGLO (betibeglogene autotemcel) for β-thalassemia to Bristol-Myers Squibb.","Total purchase price of $95 million paid in cash at closing on January 5, 2023.","Sale closed simultaneously with execution of Asset Purchase Agreement; no assumed liabilities.","Proceeds provide capital infusion; no specific use of proceeds disclosed.","PRV transfer required FDA notification within 14-30 days post-closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-002980","json":"https://secwatch.observer/filing/0001193125-23-002980.json","markdown":"https://secwatch.observer/filing/0001193125-23-002980.md","text":"https://secwatch.observer/filing/0001193125-23-002980.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/0001193125-23-002980-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/d435443d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:38:31.194730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f55db7fcaa4327cc17ab6040ad9727fa805aa810","claim":"bluebird bio, Inc. completed a disposition involving Bristol-Myers Squibb Company for $95 million (closed 2023-01-05).","evidence_excerpt":"Pursuant to the PRV Transfer Agreement, Buyer agreed to pay the Company $95 million, payable in cash, upon the closing of the sale, which occurred simultaneously with the parties entering into the PRV Transfer Agreement.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/0001193125-23-002980-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company"},{"label":"Consideration","value":"$95 million"},{"label":"Closing","value":"2023-01-05"}],"fact_type":"ma_transaction"},{"claim_id":"89fb4a41000c8b341484345205e04bbe8117d673","claim":"bluebird bio, Inc. entered into PRV Transfer Agreement with Bristol-Myers Squibb Company valued at $95 million (effective 2023-01-05).","evidence_excerpt":"On January 5, 2023, bluebird bio, Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”) with Bristol-Myers Squibb Company (“Buyer”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to Buyer.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/0001193125-23-002980-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company"},{"label":"Value","value":"$95 million"},{"label":"Effective","value":"2023-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}